Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: a pooled analysis of individual patient data from three randomized trials

Willem J A Witlox; Bram L T Ramaekers; Benjamin Lacas; Cecile Le Pechoux; Alexander Sun; Si-Yu Wang; Chen Hu; Mary Redman; Vincent van der Noort; Ning Li; Matthias Guckenberger; Harm van Tinteren; Harry J M Groen; Manuela A Joore; Dirk K M De Ruysscher

doi:10.1016/j.radonc.2021.09.029

Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: a pooled analysis of individual patient data from three randomized trials

Willem J A Witlox^*, Bram L T Ramaekers, Benjamin Lacas, Cecile Le Pechoux, Alexander Sun, Si-Yu Wang, Chen Hu, Mary Redman, Vincent van der Noort, Ning Li, Matthias Guckenberger, Harm van Tinteren, Harry J M Groen, Manuela A Joore, Dirk K M De Ruysscher

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We assessed the impact of different PCI fractionation schedules (30 Gy in 10 versus 15 fractions) on brain metastases-free survival (BMFS) and toxicity in stage III NSCLC. Our results suggest that 30 Gy in 10 fractions is associated with increased toxicity, while no conclusive evidence of improving BMFS was seen with this schedule. (c) 2021 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 164 (2021) 163-166 This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Original language	English
Pages (from-to)	163-166
Number of pages	4
Journal	Radiotherapy and Oncology
Volume	164
Early online date	4 Oct 2021
DOIs	https://doi.org/10.1016/j.radonc.2021.09.029
Publication status	Published - Nov 2021

Keywords

Brain metastases-free survival
CHEMORADIOTHERAPY
HIGH-RISK
Non-small cell lung cancer
Prophylactic cranial irradiation
RADIATION-THERAPY
RTOG 0212
Toxicity

Access to Document

10.1016/j.radonc.2021.09.029Licence: CC BY

Cite this

Witlox, W. J. A., Ramaekers, B. L. T., Lacas, B., Pechoux, C. L., Sun, A., Wang, S.-Y., Hu, C., Redman, M., van der Noort, V., Li, N., Guckenberger, M., van Tinteren, H., Groen, H. J. M., Joore, M. A., & De Ruysscher, D. K. M. (2021). Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: a pooled analysis of individual patient data from three randomized trials. Radiotherapy and Oncology, 164, 163-166. https://doi.org/10.1016/j.radonc.2021.09.029

Witlox, Willem J A ; Ramaekers, Bram L T ; Lacas, Benjamin et al. / Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer : a pooled analysis of individual patient data from three randomized trials. In: Radiotherapy and Oncology. 2021 ; Vol. 164. pp. 163-166.

@article{d6dee640a7b04da4b9656a0aeb6db253,

title = "Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: a pooled analysis of individual patient data from three randomized trials",

abstract = "We assessed the impact of different PCI fractionation schedules (30 Gy in 10 versus 15 fractions) on brain metastases-free survival (BMFS) and toxicity in stage III NSCLC. Our results suggest that 30 Gy in 10 fractions is associated with increased toxicity, while no conclusive evidence of improving BMFS was seen with this schedule. (c) 2021 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 164 (2021) 163-166 This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).",

keywords = "Brain metastases-free survival, CHEMORADIOTHERAPY, HIGH-RISK, Non-small cell lung cancer, Prophylactic cranial irradiation, RADIATION-THERAPY, RTOG 0212, Toxicity",

author = "Witlox, {Willem J A} and Ramaekers, {Bram L T} and Benjamin Lacas and Pechoux, {Cecile Le} and Alexander Sun and Si-Yu Wang and Chen Hu and Mary Redman and {van der Noort}, Vincent and Ning Li and Matthias Guckenberger and {van Tinteren}, Harm and Groen, {Harry J M} and Joore, {Manuela A} and {De Ruysscher}, {Dirk K M}",

year = "2021",

month = nov,

doi = "10.1016/j.radonc.2021.09.029",

language = "English",

volume = "164",

pages = "163--166",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

Witlox, WJA , Ramaekers, BLT, Lacas, B, Pechoux, CL, Sun, A, Wang, S-Y, Hu, C, Redman, M, van der Noort, V, Li, N, Guckenberger, M, van Tinteren, H, Groen, HJM, Joore, MA & De Ruysscher, DKM 2021, 'Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: a pooled analysis of individual patient data from three randomized trials', Radiotherapy and Oncology, vol. 164, pp. 163-166. https://doi.org/10.1016/j.radonc.2021.09.029

Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: a pooled analysis of individual patient data from three randomized trials. / Witlox, Willem J A ; Ramaekers, Bram L T; Lacas, Benjamin et al.
In: Radiotherapy and Oncology, Vol. 164, 11.2021, p. 163-166.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer

T2 - a pooled analysis of individual patient data from three randomized trials

AU - Witlox, Willem J A

AU - Ramaekers, Bram L T

AU - Lacas, Benjamin

AU - Pechoux, Cecile Le

AU - Sun, Alexander

AU - Wang, Si-Yu

AU - Hu, Chen

AU - Redman, Mary

AU - van der Noort, Vincent

AU - Li, Ning

AU - Guckenberger, Matthias

AU - van Tinteren, Harm

AU - Groen, Harry J M

AU - Joore, Manuela A

AU - De Ruysscher, Dirk K M

PY - 2021/11

Y1 - 2021/11

N2 - We assessed the impact of different PCI fractionation schedules (30 Gy in 10 versus 15 fractions) on brain metastases-free survival (BMFS) and toxicity in stage III NSCLC. Our results suggest that 30 Gy in 10 fractions is associated with increased toxicity, while no conclusive evidence of improving BMFS was seen with this schedule. (c) 2021 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 164 (2021) 163-166 This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

AB - We assessed the impact of different PCI fractionation schedules (30 Gy in 10 versus 15 fractions) on brain metastases-free survival (BMFS) and toxicity in stage III NSCLC. Our results suggest that 30 Gy in 10 fractions is associated with increased toxicity, while no conclusive evidence of improving BMFS was seen with this schedule. (c) 2021 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 164 (2021) 163-166 This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

KW - Brain metastases-free survival

KW - CHEMORADIOTHERAPY

KW - HIGH-RISK

KW - Non-small cell lung cancer

KW - Prophylactic cranial irradiation

KW - RADIATION-THERAPY

KW - RTOG 0212

KW - Toxicity

U2 - 10.1016/j.radonc.2021.09.029

DO - 10.1016/j.radonc.2021.09.029

M3 - Article

C2 - 34619235

SN - 0167-8140

VL - 164

SP - 163

EP - 166

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

ER -

Witlox WJA , Ramaekers BLT, Lacas B, Pechoux CL, Sun A, Wang SY et al. Association of different fractionation schedules for prophylactic cranial irradiation with toxicity and brain metastases-free survival in stage III non-small cell lung cancer: a pooled analysis of individual patient data from three randomized trials. Radiotherapy and Oncology. 2021 Nov;164:163-166. Epub 2021 Oct 4. doi: 10.1016/j.radonc.2021.09.029